Pegylated Liposomal Doxorubicin in the Treatment of Primary Cutaneous T-Cell Lymphomas

Haematologica - Italy
doi 10.3324/haematol.10879
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Ferrata Storti Foundation (Haematologica)

Related search

Gemcitabine Plus Liposomal Doxorubicin for Relapsed Refractory T-Cell Lymphomas

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

An Overview of Cutaneous T Cell Lymphomas

F1000Research
GeneticsMolecular BiologyPharmacologyBiochemistryMicrobiology ImmunologyMedicineToxicologyPharmaceutics
2016English

Primary Cutaneous Acral CD8+ T-Cell Lymphomas Relapse More Frequently in Younger Patients

British Journal of Haematology
Hematology
2018English

Emerging Pharmacotherapies in Ovarian Cancer: Focus on Pegylated Liposomal Doxorubicin

Clinical Medicine Reviews in Women's Health
2010English

Vorinostat Approved in Japan for Treatment of Cutaneous T-Cell Lymphomas: Status and Prospects

OncoTargets and Therapy
OncologyPharmacology
2012English

Efficacy and Safety of Non-Pegylated Liposomal Doxorubicin in Metastatic Breast Cancer Therapy

OnCOReview
Oncology
2017English

Pegylated Liposomal Doxorubicin Combined With Cyclophosphamide, Vincristine/Vindesine, and Prednisone in Patients With Aggressive T-Cell Lymphoma: Preliminary Results of Aphase Ii Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Japanese Guidelines for Cutaneous Lymphomas: Cutaneous Adult T Cell Leukemia/Lymphoma (ATLL)

Skin Cancer
2008English

Modeling Pegylated Liposomal Doxorubicin-Induced Hand-Foot Syndrome and Intestinal Mucositis in Zebrafish

OncoTargets and Therapy
OncologyPharmacology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy